BindingDB logo
myBDB logout

BDBM205221 US9546152, example 84

SMILES: COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1

InChI Key: InChIKey=YYMYXFQABPEWJD-CZUORRHYSA-N

Data: 4 KI  4 IC50

Find this compound or compounds like it in BindingDB or PDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 205221   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kcal/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Orexin receptor type 2


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt
UniProtKB/TrEMBL

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
2n/an/an/an/an/an/an/an/a



MERCK SHARP & DOHME CORP.

US Patent


Assay Description
Radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which the inhibition constant (Ki) is determ...


US Patent US9546152 (2017)


BindingDB Entry DOI: 10.7270/Q2D50PZW
More data for this
Ligand-Target Pair
Orexin receptor type 2


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt
UniProtKB/TrEMBL

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
PubMed
2n/an/an/an/an/an/an/an/a



Merck& Co.

Curated by ChEMBL


Assay Description
Displacement of [3H](S)-N-(2-(1H-pyrrol-1-yl)phenyl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX2R exp...


Bioorg Med Chem Lett 27: 1364-1370 (2017)


BindingDB Entry DOI: 10.7270/Q2WH2S8Q
More data for this
Ligand-Target Pair
Orexin receptor type 1


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
PubMed
2.52E+3n/an/an/an/an/an/an/an/a



Merck& Co.

Curated by ChEMBL


Assay Description
Displacement of [3H](S)-N-(biphenyl-2-yl)-1-(2-(1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX1R expressed in C...


Bioorg Med Chem Lett 27: 1364-1370 (2017)


BindingDB Entry DOI: 10.7270/Q2WH2S8Q
More data for this
Ligand-Target Pair
Orexin receptor type 1


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
2.52E+3n/an/an/an/an/an/an/an/a



MERCK SHARP & DOHME CORP.

US Patent


Assay Description
Radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which the inhibition constant (Ki) is determ...


US Patent US9546152 (2017)


BindingDB Entry DOI: 10.7270/Q2D50PZW
More data for this
Ligand-Target Pair
Orexin receptor type 2


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt
UniProtKB/TrEMBL

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
PubMed
n/an/a 22n/an/an/an/an/an/a



Merck& Co.

Curated by ChEMBL


Assay Description
Antagonist activity at human OX2R expressed in CHOK1 cells assessed as reduction in orexin A-induced calcium flux preincubated followed by orexin A a...


Bioorg Med Chem Lett 27: 1364-1370 (2017)


BindingDB Entry DOI: 10.7270/Q2WH2S8Q
More data for this
Ligand-Target Pair
Orexin receptor type 1


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
PubMed
n/an/a>1.00E+4n/an/an/an/an/an/a



Merck& Co.

Curated by ChEMBL


Assay Description
Antagonist activity at human OX1R expressed in CHOK1 cells assessed as reduction in orexin A-induced calcium flux preincubated followed by orexin A a...


Bioorg Med Chem Lett 27: 1364-1370 (2017)


BindingDB Entry DOI: 10.7270/Q2WH2S8Q
More data for this
Ligand-Target Pair
Orexin receptor type 2


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt
UniProtKB/TrEMBL

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a 22n/an/an/an/an/an/a



MERCK SHARP & DOHME CORP.

US Patent


Assay Description
The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...


US Patent US9546152 (2017)


BindingDB Entry DOI: 10.7270/Q2D50PZW
More data for this
Ligand-Target Pair
Orexin receptor type 1


(Homo sapiens (Human))
BDBM205221
PNG
(US9546152, example 84)
Show SMILES COc1ccc(C(=O)N2C[C@@H](CC[C@H]2C)Oc2nccc(C#N)c2C)c(SC)n1 |r|
Show InChI InChI=1S/C21H24N4O3S/c1-13-5-6-16(28-19-14(2)15(11-22)9-10-23-19)12-25(13)21(26)17-7-8-18(27-3)24-20(17)29-4/h7-10,13,16H,5-6,12H2,1-4H3/t13-,16-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/a>1.00E+4n/an/an/an/an/an/a



MERCK SHARP & DOHME CORP.

US Patent


Assay Description
The utility of the compounds in accordance with the present invention as orexin receptor OX1R and/or OX2R antagonists may be readily determined witho...


US Patent US9546152 (2017)


BindingDB Entry DOI: 10.7270/Q2D50PZW
More data for this
Ligand-Target Pair